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Background: Recent studies demonstrated that engagement of sodium glucose transporter 1 (SGLT-1) by orally
administered D-glucose protects the intestinal mucosa from lipopolysaccharide (LPS)-induced injury. We tested
whether SGLT-1 engagement might protect the intestinal mucosa from doxorubicin (DXR)- and 5-fluorouracil
(5-FU)-induced injury in animal models mimicking acute or chronic mucositis.
Methods: Mice were treated intraperitoneally with DXR, alone or in combination with 5-FU, and orally with BLF501,
a glucose-derived synthetic compound with high affinity for SGLT-1. Intestinal mucosal epithelium integrity was
assessed by histological analysis, cellular proliferation assays, real-time PCR gene expression assays and Western blot
assays. Student’s t-test (paired two-tailed) and χ2 analyses were used for comparisons between groups. Differences
were considered significant at p < 0.05.
Results: BLF501 administration in mice treated with DXR and/or 5-FU decreased the injuries to the mucosa in terms
of epithelial integrity and cellular proliferative ability. Co-treatment with BLF501 led to a normal expression and
distribution of both zonula occludens-1 (ZO-1) and beta-catenin, which were underexpressed after treatment with
either chemotherapeutic agent alone. BLF501 administration also restored normal expression of caspase-3 and
ezrin/radixin/moesin (ERM), which were overexpressed after treatment with DXR and 5-FU. In SGLT1-/- mice, BLF501
had no detectable effects. BLF501 administration in wild-type mice with growing A431 tumors did not modify
antitumor activity of DXR.
Conclusions: BLF501-induced protection of the intestinal mucosa is a promising novel therapeutic approach to
reducing the severity of chemotherapy-induced mucositis.
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Oral and gastrointestinal mucositis are serious side ef-
fects of chemotherapy. Severe mucositis is especially
common among patients who receive aggressive myeloa-
blative chemotherapy and in patients who receive therapy
for head and neck cancer [1-3]. Mucositis is a complex,
multifactorial process which affects all layers of the gastro-
intestinal tract [4,5] and is characterized by apoptosis and* Correspondence: cristiano.rumio@unimi.it
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reproduction in any medium, provided the orreduced proliferation of epithelial cells in the intestinal
crypts, villus atrophy and collagen breakdown. Mucositis
impedes the efficacy of treatment protocols because it
may require chemotherapy interruption, reduction in drug
dosages or change to other antitumor drugs [6-8]. Treat-
ment of mucositis is mainly symptomatic. In recent years,
Palifermin has been successfully adopted for treatment of
oral mucositis during chemotherapy of hematologic can-
cers [9]. However, except for “guidelines” for symptom
management, no well-established therapeutic strategies
to treat chemotherapy-induced intestinal mucositis are
available [10-12]. Thus the development of an effectivel Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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high priority in oncological supportive care [13,14].
The sodium-glucose cotransporter 1 (SGLT-1) is a high-
capacity glucose transporter expressed mainly in the apical
membrane of epithelial cells lining the S3 segment of
the proximal renal tubule and the intestinal epithelium
[15,16]. SGLT-1 is the most important transporter of
D-glucose and D-galactose from the small intestinal lumen
into enterocytes and is upregulated in response to glucose
in food [17]. Recent reports suggest additional roles for
SGLT-1 which may not be directly linked to transport. For
example, expression of SGLT-1 was shown to be necessary
to preserve the integrity of plasma membranes and tight
junctions in tubular renal epithelial cells after exposure
to cisplatin in vitro [16,18]. Moreover, we have shown
in a mouse model of septic shock that oral administra-
tion of high doses of D-glucose or the non-metabolized
glucose analog 3-0-methyl-D-glucopyransoide protected
the intestinal epithelium from lipopolysaccharide-induced
inflammatory injury [19,20]. Based on these data, we
speculated that SGLT-1-mediated signaling might be
beneficial in maintaining intestinal mucosal integrity from
chemotherapy-induced damage. To test this hypothesis,
we examined the effects of BLF501 (formerly called “com-
pound 5”), a synthetic compound which binds to SGLT-1
withdrawal [21], in a mouse model of doxorubicin (DXR)-
and 5-fluorouracil (5-FU)-induced intestinal injury. Here,
we show that BLF501-induced SGLT-1 activation protects
against DXR- and 5-FU-induced injury by promoting
proliferation of enterocytes and correct formation of tight
and adherens junctions. BLF501 does not appear to inter-
fere with drug antitumor activity.
Results
Oral administration of BLF501 protects against alterations
of the small intestine induced by a single administration
of DXR
The effect of BLF501 on alterations of the small intestine
induced by DXR was evaluated in mice treated with: DXR
alone (20 mg/kg i.p., n = 14); DXR plus BLF501 (25 μg/kg
BLF501, n = 14); BLF501 alone (n = 14); or left untreated
(n = 7). Half of the mice were sacrificed after 48 h and the
other half, after 72 h (Table 1). The same evaluations was
performed on SGLT-1-/- mice after 72 h of treatment with
DXR with or without BLF501 co-treatment (Table 1).
Macroscopic examination of small intestine samples
collected at 48 or 72 h revealed only early-stage mor-
phological alterations, whereas immunofluorescence BrdU
assay revealed a significantly reduced proliferation rate of
crypt cells in DXR-treated mice [DXR 1.3 ± 0.2% at 48 h;
0.8 ± 0.6% at 72 h, UNTR 2.3 ± 2.2% at 72 h; UNTR vs
DXR, p = 0.0086 (48 h) and p = 0.023 (72 h)] that was ab-
sent in mice treated simultaneously with DXR and BLF501
[DXR+ BLF501 3.3 ± 0.5% and 2.2 ± 0.5% at 48 and 72 h,respectively; DXR+ BLF501 vs DXR p = 0.004 (48 h) and
p = 0.028 (72 h)] (Figure 1). In SGLT1-/- mice, proliferation
was dramatically increased compared to that in wild-type
mice, but no modification of intestinal epithelial cell prolif-
eration was observed in samples from mice treated with
BLF501 alone. BLF501 proved to be inactive in SGLT-1-/-
mice, with no improvements in cellular proliferation rate
observed at 72 h after DXR treatment in combination with
BLF501 (mean ± SD, UNTR, 11.09 ± 1.93%; DXR, 7.38 ±
2.71%; DXR + BLF501, 8.24 ± 4.59%. UNTR vs DXR, p =
0.0012; DXR vs DXR+ BLF501, p = 0.3870).
Expression of beta-catenin, a unique intracellular
protein functioning as an integral component of the
cell-cell adhesion complex and as a principal signaling
protein in the canonical Wnt pathway linked to cell
proliferation [22,23], was reduced at 48 h after DXR
administration in the villi and, at 72 h, in both villi
and crypts of wild-type mice. Treatment with BLF501
was found to maintain the physiological expression of
beta-catenin (Figure 2).
Further analysis of the protective effect of BLF501 fo-
cused on the expression of different genes implicated in
the early response to tissue injury [24], including: DLL-1, a
marker of crypt cells actively proliferating in a stem cell-
like manner [25]; TFF-3 and beta-actin, components of the
mucus layer [26] and the cytoskeleton, respectively, and
whose reduced expression mirrors decreased mucin pro-
duction and alteration of cytoskeletal structure, respect-
ively; and sucrose isomaltase, a marker for brush border
integrity [24] and a key enzyme in carbohydrate metabol-
ism, whose reduced expression mirrors epithelial damage
and nutrient malabsorption [27]. Expression of all of these
markers was reduced at 48 h after DXR treatment, but,
after co-treatment with BLF501, was similar to that in con-
trol mice (Figure 3).
BLF501 protects the small intestine mucosa from injury
induced by repeated administration of DXR and 5-FU
We also evaluated the effect of BLF501 in a mouse model
of DXR- and 5-FU-induced mucositis. The addition of
5-FU is necessary to stabilize and standardize DXR action,
reducing the variability of epithelial damages in this model
mimicking medium-term chemotherapy-induced effects
on the intestinal mucosa, in particular, morphology and
cellular population alterations and junctional systems in-
tegrity [24,28-30]. Intestinal epithelium from mice treated
with the two chemotherapeutics was extensively damaged
(Figure 4A-F). In particular, villi were atrophic, fused and
reduced in height (-36.15 ± 2.56% vs untreated); epithelial
cells were hyperplastic and brush borders had large areas
of erosion; focal ectasia of chyliferous vessels was detect-
able; numbers of goblet cells were decreased (DXR + 5-FU
2.56 ± 1.28% vs untreated 7.13 ± 0.64%, P = 0.0065); and
cells undergoing mitosis and cellular infiltrates rich in
Table 1 Summary of in vivo treatments
I. BLF501 action/single DXR injection
Mouse strain Group Mice/Group DXR BLF501
25 μg/kg
Sacrifice 48 h Sacrifice 72 h BrdU injection
BALB/C UNTR N = 7 - - - N = 7 +
DXR N = 14 (7 + 7) + - N = 7 N = 7 +
DXR +BLF501
25 μg/kg
N = 14 (7 + 7) + + N = 7 N = 7 +
BLF501
25 μg/kg
N = 14 (7 + 7) - + N = 7 N = 7 +
Mouse strain Group Mice/Group DXR BLF501
25 μg/kg
Sacrifice 48 h Sacrifice 72 h BrdU injection
C57 SGLT-1 -/- UNTR N = 7 - - - N = 7 +
DXR N = 7 + - - N = 7 +
DXR +BLF501
25 μg/kg
N = 7 + + - N = 7 +
II. BLF501 action/repeated DXR plus 5-FU injections
Mouse strain Group Mice/Group DXR +5-FU BLF501
0.25 μg/kg
BLF501 2.5 μg/kg BLF501
25 μg/kg
Treatment days Sacrifice day
BALB/C UNTR N = 7 - - -
Day 19
DXR + 5FU N = 7 + - Days 1, 8 and 15
DXR + 5FU +BLF501
0.25 μg/kg
N = 7 + +
DXR + 5FU +BLF501
2.5 μg/kg
N = 7 + - +
DXR + 5FU +BLF501
25 μg/kg
N = 7 + - - +
BLF501 25 μg/kg N = 7 - - - +
III. BLF501/DXR interaction
Mouse strain Group Mice/Group DXR BLF501
25 μg/kg
Treatment days Sacrifice day
SKH-1 UNTR N = 8 - - - Day 26
DXR N = 8 + - Days 7, 14 and 21
after cell injection
DXR +BLF501
25 μg/kg
N = 8 + +
BLF501 N = 8 - +
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with 25 μg/kg BLF501 showed substantial recovery from
chemotherapy-induced injury to the intestinal mucosa
(villus height: -12.31 ± 1.58%, p = 0.0014 vs untreated;
goblet cells: 6.93 ± 0.63%, p = 0.0383 vs untreated). At
2.5 μg/kg, BLF501 improved morphological parameters
(villus height: -16.82 ± 1.33%, p = 0.0026 vs untreated), but
was ineffective against loss of goblet cells (2.2 ± 1.72%) and
appearance of mitotic cells; at 0.25 μg/kg, BLF501 had no
effect on any of the parameters examined. Samples from
the intestinal epithelia of mice treated with BLF501 alone
were identical to those of control mice. Figure 4G summa-
rizes these results.
To examine the junctional systems of the intestinal epi-
thelia of mice treated with the chemotherapeutics alone ortogether with BLF501, we focused on the expression of
ZO-1, which mirrors the integrity of tight junctions [31,32],
and beta-catenin, a component of adherens junctions [33].
Immunofluorescence and immunohistochemical staining of
junctional systems revealed decreased expression of ZO-1
and an altered distribution of beta-catenin, respectively, in
intestinal samples from DXR/5-FU-treated mice, whereas
samples from mice that also received BLF501 at 25 μg/kg
showed the typical honeycomb distribution of ZO-1 and ex-
pression/distribution of beta-catenin similar to that in con-
trol mice; the 2.5 μg/kg BLF501 dose was less effective.
BLF501 (25 μg/kg) alone did not alter the expression or dis-
tribution of either ZO-1 or beta-catenin (Figure 5A-J).
We then evaluated extracts of small intestine samples
for the expression of ERM proteins, which play a crucial
Figure 1 Preservation of cell proliferation by BLF501 in small intestinal crypts of mice treated with a single administration of DXR.
Immunofluorescence assay for BrdU-positive proliferating cells was performed. DXR-induced decrease of proliferation rate apoptosis was observed
at the three- to six-cell positions within crypts. Positive cells count was performed. (A) UNTR, untreated; (B) BLF501 25 μg/kg; (C) DXR 48 h;
(D) DXR 72 h; (E) DXR + BLF501 25 μg/kg 48 h; (F) DXR + BLF501 25 μg/kg 72 h. DXR + BLF501 25 μg/kg 48 h vs DXR 48 h, ** p = 0.004; DXR +
BLF501 25 μg/kg 72 h vs DXR 72 h, * p = 0.0282. Experiments were performed in triplicate.
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Figure 2 Treatment with BLF501 maintained normal levels of beta-catenin expression in the small intestine of mice treated with a single
dose of DXR. Immunohistochemical analysis of beta-catenin: (A, B) UNTR, untreated; (C, D) BLF501 25 μg/kg; (E, F) DXR + 5-FU 48 h; (G, H) DXR +
5-FU + BLF501 25 μg/kg 48 h; (I, J) DXR + 5-FU 72 h; (K, L) DXR + 5-FU+ BLF501 25 μg/kg 72 h. Bars: 20 μm. Experiments were performed in triplicate.
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to interact with transmembrane proteins and cytoskeleton
[34], and caspase-3, an apoptosis marker whose expression
is increased by chemotherapeutic treatment [35]. Adminis-
tration of DXR and 5-FU induced overexpression of ERMFigure 3 Real-time PCR gene expression analysis of different targets im
(C) beta-actin; (D) sucrase isomerase. Expression of all of these markers was re
after co-treatment with DXR plus BLF501. Error Bars means SD. Experiments wproteins and caspase-3, whereas co-administration of
BLF501 (25 μg/kg) reduced caspase-3 expression and
restored normal levels of expression of ERM proteins.
Protein expression was normalized to that of GAPDH
(Figure 5K-M).plicated in the early response to tissue injury. (A) DLL-1; (B) TFF-3;
duced at 48 h after DXR treatment, but was similar to that in control mice
ere performed in triplicate.
Figure 4 Dose-dependent BLF501-induced protection from injury to the mucosa of the small intestine in mice repeatedly injected with
DXR and 5-FU. Histopathological detection of: (A) UNTR, untreated; (B) DXR + 5-FU; (C) DXR + 5-FU + BLF501 2.5 μg/kg; (D) DXR + 5-FU + BLF501
25 μg/kg; (E) BLF501 25 μg/kg; (F) DXR + 5-FU luminal bacterial content. (G) Summary of evaluated parameters. Statistical analysis: villus length,
DXR + 5-FU + BLF501 25 μg/kg vs DXR + 5FU, ** p = 0.0014; DXR + 5FU + BLF501 2.5 μg/kg vs DXR + 5-FU, ** p = 0.0026. Percentage of goblet cells:
DXR + 5-FU + BLF501 25 μg/kg vs DXR + 5-FU, * p = 0.0383. Damage score: +++ SEVERE; ++ MILD; + LIGHT; 0 ABSENT (A-E). Bars: 20 μm. Results
are from triplicate determinations.
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antitumor activity of DXR
Overexpression of SGLT-1 is a survival strategy utilized by
several tumor types, including EGFR-positive tumors [36].
Analysis of athymic (nude) mice injected subcutaneously
with A431 cells, which strongly express both EGFR and
SGLT-1 [37], showed that the tumor growth rate in mice
co-treated with both DXR and BLF501 was similar to that
in mice treated with DXR alone (p = 0.1836) (Figure 6),
indicating that oral administration of BLF501 does not
interfere with DXR antitumor activity. Interestingly, whileDXR-treated mice showed an average reduction of body
weight at the end of experiment, a slight increase in weight
was observed in the group of mice treated with DXR
and BLF501. No differences in tumor growth rate were
observed between untreated mice and mice treated with
BLF501 alone.
Discussion
The present data indicate that engagement of SGLT-1 by
the synthetic D-glucose analog BLF501 promotes the
protection of intestinal epithelial structures from injury
Figure 5 Preservation of tight junction and adherence junction integrity by BLF501 in mice repeatedly injected with DXR and 5FU,
stabilizing ZO-1 and beta-catenin expression and distribution. ZO-1 immunofluorescence assay: (A) UNTR, untreated; (B) DXR + 5-FU;
(C) BLF501 25 μg/kg; (D) DXR + 5-FU + BLF501 2.5 μg/kg; (E) DXR + 5-FU + BLF501 25 μg/kg. Magnification 60X. Immunohistochemical analysis of
beta-catenin: (F) UNTR, untreated; (G) DXR + 5-FU; (H) DXR + 5-FU + BLF501 2.5 μg/kg; (I) DXR + 5-FU + BLF501 25 μg/kg; (J) BLF501 25 μg/kg.
Magnification 40X. Western blot assay for epithelial damage markers caspase 3 (K), ERM complex (L), and GAPDH as housekeeping protein (M).
Experiments were performed in triplicate.
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dependent of glucose metabolism, since BLF501 is a C-
glycoside and, as such, does not enter the metabolic
pathways of D-glucose [21]. The protective effect of the
orally-administered SGLT-1 agonist 3-O-methyl-glucose
(3-OMG), a non-metabolizable analog of D-glucose
that does not enter glucose metabolic pathways, and of
D-glucose has been previously reported in a model of
LPS-induced injury to the intestinal mucosa [19]. It is
noteworthy that the dose of BLF501 necessary to protect
from DXR-induced injury was much lower than doses of
D-glucose or 3-OMG shown to protect from LPS-induced
injury (25 μg/kg vs 2.5 g/kg). The ability of BLF501 toprotect at low doses may reflect its high affinity for SGLT-
1, a possibility supported by our previous in vitro finding
that both D-glucose and BLF501 block LPS-induced re-
lease of IL-8, yet BLF501 is active at doses ~106-fold lower
than that of D-glucose [21].
Regarding the mechanism underlying the therapeutic
effect of BLF501, oral administration indirectly protects
the intestinal epithelium from chemotherapy-induced injury
which was detectable at 48 h and was almost complete at
72 h after a single administration of DXR. Cellular prolifera-
tion assays performed on SGLT-1-/- mice demonstrate the
pivotal role of SGLT-1 engagement by BLF501 to exert
ligand biological activity; in fact, in the absence of SGLT-1,
Figure 6 Tumor growth rate and weight in mice treated with chemotherapy alone or in conjunction with BLF501. Oral administration of
BLF501 did not interfere with the antitumor activity of DXR. DXR-treated mice showed a reduction of body weight at the end of experiment,
while a slight weight increase was observed in mice treated with DXR and BLF501. Error bars means SD Experiments were performed in triplicate.
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after BLF501 administration. Differences between the mean
values of cell proliferation detected in wild-type and SGLT-
1-/- mice probably reflect existing physiological differences
between the BALB/C and C57 strains or an altered metab-
olism in SGLT-1-/- vs wild-type mice.
Among the different modifications observed upon co-
administration of BLF501 with chemotherapeutics, we
found reduced expression of caspase-3 in the intestines
of co-treated mice compared to those treated with che-
motherapeutics alone. This is likely due to a decrease in
apoptotic events, consistent with recent reports that glu-
cose administration reduces LPS-induced apoptotic events
in enterocytes both in vitro and in vivo [16,38]. We also
observed maintenance of the integrity of tight junctions in
intestinal epithelia upon administration of BLF501 in mice
treated with DXR and/or 5-FU, consistent with previous
studies demonstrating that in the presence of heat- or
chemical-induced sub-lethal stress conditions, activation of
SGLT-1 preserves the integrity of tight junctions [16,18]. In
particular, small intestine samples from mice treated with
DXR and 5-FU showed altered expression and distribu-
tion of the junctional proteins ZO-1 and beta-catenin,
whereas in mice co-treated with BLF501, ZO-1 and beta-
catenin were normally expressed and distributed. More-
over, the ERM complex, which has a physiological role in
the remodeling of junctional mechanisms [17,39-43], over-
expressed upon treatment of DXR and 5-FU treatment
causing the opening of junctional systems; BLF501 co-treatment maintained ERM expression into normal levels
in mice co-treated with BLF501.
In our mucositis models, BLF501 was found to preserve
proliferation and integrity of junctional systems, as well as
to reduce the expression of a marker of apoptosis. These
beneficial effects on the overall integrity of the epithelium
were confirmed histologically. These findings strongly favor
the use of BLF501 as a therapeutic tool for the maintenance
of the integrity of the intestinal epithelium in the setting of
chemotherapy-induced injury. In fact, chemotherapeutics
induce apoptotic cell death and inhibit proliferation in rap-
idly dividing epithelia such as the intestinal epithelium [44].
As a consequence, mucosal atrophy and a reduction of the
absorption capacity of the intestine ensue, leading to further
deterioration of the general condition of patients who are
already heavily compromised.
The mechanism of interaction between SGLT-1 and its
ligand BLF501 remains unknown. However based on sev-
eral published findings [42,45,46] and as schematized in
Figure 7, we hypothesize that BLF501-induced SGLT-1 en-
gagement initiates downstream cellular signaling involving
MAPKPK-2 and AKT-2 with consequent GSK-3 phospho-
rylation. P-GSK-3 acts to inhibit p53-induced casapse-3
cleavage and to preserve the phosphorylated beta-catenin
cytoplasmic pool, with positive effects on cellular prolifera-
tion mechanisms. At the same time, AKT-2 activation
modulates tight junction expression via the ERM complex.
Clarification of the cellular pathways involved in the pro-
tective activity of BLF501 awaits further in-depth analyses.
Figure 7 Hypothetical cellular pathways activated by BLF501-mediated SGLT-1 engagement. MAPKAPK-2/AKT-2 activation induces GSK-3
phosphorylation and consequent inhibition of p53–mediated caspase-3 cleavage. P-GSK-3 also preserves the cytoplasmic pool of beta-catenin
involved in cellular proliferation mechanisms. Akt-2 is a key effector involved in tight junction management via ERM complex modulation.
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tion of the non-metabolizable glucose analog BLF501
protects the intestinal mucosa from injuries induced by
chemotherapeutic drugs. This suggests the prophylactic
and/or therapeutic promise of BLF501 for the prevention
or reduction of the severity of chemotherapy-induced
mucositis. Moreover, orally administered BLF501 does
not appear to interfere with the antitumor activity of
the chemotherapeutics, with no difference in tumor
growth between mice treated with DXR or DXR plus
BLF501.Materials and methods
Cells and culture conditions
A431 cells were purchased from ATCC (Rockville, MD)
and authenticated using a panel of microsatellite markers
(Istituto Nazionale Tumori, Milano, Italy). Cells were
cultured in RPMI 1640 medium (Euroclone, Pero, Italy)
supplemented with 10% FBS (Euroclone), 1% glutamine
(Euroclone) and 1% penicillin/streptomycin solutions
(Euroclone). A431 cells in log phase were digested and
cell suspensions were inoculated subcutaneously under
sterile conditions into mice.C-glycoside BLF501
The synthesis and a preliminary profiling of BLF501 have
been described [21]. BLF501 resembles the structure (isos-
teric) of the natural O-glycoside, but cannot be metabolized
(C-glycosides are unable to undergo glycolysis). BLF501 iswater-soluble (5 mM) and stable for several days at 25°C at
pH 1-12 (stored in the dark).
Mice and in vivo treatments
Eight-week-old female BALB/c and nude SKH-1 mice were
purchased from Charles River Italy (Calco, Italy). SGLT-1-/-
mice on a C57BL/6 background have recently been de-
scribed [17]. Mice were housed in specific aseptic condi-
tions at constant temperature and humidity, with food and
water given ad libitum. Mice were fed a specific normoca-
loric chow which does not contain glucose and galactose
(Altromin C1000, Rieper, BZ, Italy). Experimental proto-
cols were approved by the Ethics Committee for Animal
Experimentation of the Istituto Nazionale Tumori (Milano,
Italy), and conducted according to the guidelines of the
United Kingdom Coordinating Committee on Cancer Re-
search for animal welfare in experimental neoplasia (1998).
The effect of BLF501 on intestinal injury induced by a
single injection of DXR (Pfizer; NY, USA) was evaluated
in four groups of BALB/C mice: controls (n = 7); DXR
(n = 14); DXR plus BLF501 (n = 14); and BLF501 (n = 14).
DXR (20 mg/kg in saline, total volume 300 μl) was admin-
istered by i.p. injection. BLF501 (25 μg/kg in saline, total
volume 100 μl) was administered at the same time by gav-
age using a gastric tube. Control mice were treated i.p.
with saline. One hour before sacrifice, bromodeoxyuridine
(BrdU, Novocastra, Newcastle, UK) was injected i.p to de-
termine cell proliferation. Control mice were sacrificed
after 72 h. Mice from the other groups were sacrificed
at 48 (n = 7) and at 72 h (n = 7) after treatment (Table 1)
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groups: UNTR; DXR; and DXR+ BLF501 25 μg/kg. (n = 7/
group) (Table 1) and sacrificed after 72 h.
The effect of BLF501 on intestinal injury induced by re-
peated injections of DXR and 5-FU (TEVA; Petah Tikva,
Israel) was evaluated in six groups (n = 7/group): controls;
DXR/5 + FU; DXR/5 + FU+BLF501 (0.25 μg/kg); DXR+ 5-
FU + BLF501 (2.5 μg/kg); DXR+ 5-FU+ BLF501 (25 μg/kg);
BLF501 (25 μg/kg). DXR (7 mg/kg) and 5-FU (100 ng/kg),
dissolved in saline solution in a final volume of 300 μl, were
administered i.p. once per week for 3 weeks. BLF501 (in sa-
line, 100 μl final volume) was administered at the same time
by gavage using a gastric tube. Mice were sacrificed on day
19 after starting treatment (Table 1).
The effect of BLF501 on the antitumor activity of DXR
was tested in four groups (n = 8/group) of nude SKH-1
mice bearing SGLT-1-positive A431 mammary tumors that
had reached a mean weight of 240 mg: controls; DXR
(6 mg/kg in 200 μl saline) + BLF501 (25 μg/kg in 100 μl sa-
line); DXR alone; BLF501 alone. DXR was administered
intravenously (i.v.) once per week for 3 weeks. BLF501 was
administered at the same time by gavage using a gastric
tube. Mice were sacrificed on day 26 of treatment (Table 1).
Statistical significance was assessed using χ2 analysis.
Processing of samples and histological evaluation
Mice were sacrificed and jejunum samples were collected
and fixed in 10% formalin with 2% sucrose in phosphate
buffer for 4 h at 4°C and processed for paraffin embedding.
Other jejunum samples were collected and preserved in li-
quid nitrogen for mRNA and protein extraction.
For histological examination, slides were stained with
hematoxylin and eosin. Histological images were captured
and digitized. Villus height was measured using Image
Pro Plus 4 image analysis software (Media Cybernetics,
Baltimore, MD). The degree of intestinal tissue injury
was evaluated on a grading scale of : +++ = severe; ++ =
mild; + = light; 0 = absent.
ZO-1 immunofluorescence
Briefly, sample sections on slides were deparaffinized and
hydrated for 1 h through a descending scale of alcohols.
After a quick rinse with 0.1 M Tris-HCl, pH 7.4, sections
were incubated with proteinase K (20 g/ml) Tris-EDTA
buffer, pH 8, for 15 min at 37°C, washed with Tris-HCl
and permeabilized with 1% Triton X-100 in Tris-HCl for
5 min. Sections were treated with blocking solution for
1 h at room temperature and incubated overnight at 4°C
with 20 μg/ml primary anti-mouse ZO-1 rabbit antibody
(α-ZO-1, Invitrogen, Camarillo, CA). After washing, sam-
ples were incubated with secondary goat anti-rabbit anti-
body conjugated to tetramethyl-rhodamine isothiocyanate
(TRITC; DyLight Jackson, West Baltimore Pike West
Grove, PA, US) diluted 1:1000 in Tris-HCl for 45 min atroom temperature. Sections were incubated with DAPI
(1:10000 in Tris-HCl) for 5 min at room temperature and
washed 3 times with Tris-HCl and 0.01% Triton X-100.
Slides were mounted with Mowiol.
Beta-catenin immunohistochemistry
Sample sections on slides were deparaffinized and hydrated
for 1 h through a descending scale of alcohols. Antigen re-
trieval was performed using two antigen unmasking steps
of 5 min in a microwave oven with citrate buffer, pH 6
(0.005 M). Sections were cooled and then washed with
0.1 M Tris-HCl, pH 7.4, + 0.025% Triton X-100. Samples
were treated with a peroxidase inhibition solution of 3%
H2O2 in 0.1 M Tris-HCl, pH 7.4, for 20 min and nonspe-
cific sites were blocked with HHG solution (1 mM Hepes,
2% goat serum, 1X HBSS, 0.5% Triton X-100) in Tris-HCl
for 1 h at room temperature. Sections were then incubated
for 2 h at room temperature with a primary anti-beta-
catenin rabbit antibody diluted 1:500 (Abcam, Cambridge,
UK), washed, and incubated for 45 min at room tem-
perature with a biotinylated secondary goat anti-rabbit
antibody diluted 1:1000. Finally, sections were incubated
with ABC-kit and DAB (Vector, Burlingame, VT, US),
counterstained with hematoxylin, dehydrated through an
ascending scale of alcohols and xylene, and mounted with
coverslips using Entellan (Merck, Darmstadt, Germany).
BrdU immunofluorescence
Sample sections on slides were deparaffinized and hy-
drated for 1 h through a descending scale of alcohols,
rinsed in PBS and incubated at room temperature with
2 N HCl for 30 min and with Na2B4O7 for 10 min. Sec-
tions were incubated with PBS/3% BSA for 20 min at
room temperature and with proteinase K (20 g/ml) Tris-
EDTA buffer, pH 8, for 15 min at 37°C. After washing,
slides were incubated for 1 h at room temperature with
a primary anti-BrdU mouse antibody (Novocastra) diluted
1:200 in PBS/3% BSA, washed, and incubated with sec-
ondary goat anti-mouse DyLight 488 antibody (Jackson)
diluted 1:500 in PBS/BSA 3%. Sections were washed, incu-
bated for 5 min at room temperature with DAPI diluted
1:2500 in PBS, and mounted with Mowiol.
All samples were observed and photographed with a
microscope Nikon Eclipse 80 with a digital camera Nikon
DS-L1.
Real-time polymerase-chain reaction (PCR)
RNA was extracted from frozen jejunum samples using
TRI-reagent (Sigma-Aldrich, St. Louis, MO, US) and
transcribed with a reverse transcription kit (Applied
Biosystems, Foster City, CA, US). Real-time PCR experi-
ments were performed according to the manufacturer’s
instructions using a 7900HT Fast Real-Time PCR Sys-
tem (Applied Biosystems). Primers for SI, TFF3, DLL1,
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Western blot analysis
Expression of caspase-3 and ERM complex was assessed
on total phosphorylated protein extracted from small in-
testine samples of mice using our TNTG buffer (40 mM
Tris, pH 7.5, 100 mM NaCl, 10% glycerol, 1% Triton X-
100, proteases inhibitors). Protein extracts were quantified
using the BCA method (BCA Protein Assay Kit, Pierce,
Rockford, IL, US). Proteins (30 μg) were fractionated on a
polyacrylamide gel (BIO-RAD Labs, Hercules, CA) and
electroblotted onto nitrocellulose filters (American Biosci-
ences, Buckinghamshire, UK). Filters were incubated for
1 h in TBS containing 5% milk powder to block nonspe-
cific binding sites, followed by anti-caspase-3 antibody
(1 μg/ml; Abcam), anti-GAPDH antibody (1:1000; Abcam)
and anti-ERM antibody (1:1000; Cell Signaling Technolo-
gies, Danvers, MA, US), and finally with appropriate anti-
goat and anti-rabbit secondary anti-peroxide antibody
(Vector Laboratories). Bands were visualized using ECL™
Western Blotting Detection Reagents and plates by auto-
radiography (American Biosciences).
Statistical analyses
Student’s t-test (paired two-tailed), χ2 analysis and Graph-
Pad Prism software (GraphPad Prism Software Inc., San
Diego, CA) were used for comparisons between groups.
Differences were considered significant at p < 0.05.
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